TheranosticTrials.org

Clinical Trial · NCT02431715

18F-FDOPA PET in Neuroendocrine Tumours

Overview

Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic. The correct treatment approach is dependent on the extent of the disease, however surgical approaches and systemic therapy can be curative. Combined positron emission tomography/computed tomography (PET/CT) using the radiotracer 18F-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) has been shown to be a promising non-invasive technique to help localizing NETs and guide their treatment.

Sponsor

British Columbia Cancer Agency

ClinicalTrials.gov

NCT02431715

Drug / Compound

FDOPA

Isotope(s):
Target(s):
  • Aromatic L-amino acid decarboxylase (AADC)
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Inclusion Criteria
  • Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70 cm).
  • Patients must be able to tolerate the physical/logistical requirements of completing a PET scan including lying flat for up to 40 minutes and tolerating intravenous cannulation for injection.Exclusion Criteria
  • Patients who are medically unstable eg. acute cardiac or respiratory distress, hypotensive
  • ECOG performance status 0 - 3.
  • Referred by a treating BC physician.
  • Patients who meet the BCCA approved clinical indications for 18F-FDOPA PET/CT scans in neuroendocrine tumours.
  • Pregnancy.

Exclusion

Exclusion criteria not yet provided.